ABSTRACT
Objective To determine the association of cannabis use-related variables and self-reported psychotic disorders during two time periods (2001-2002; 2012-2013).
Methods Logistic regression was used to analyze data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, 2001-2002; N=43,093) and NESARC-III (2012-2013; N=36,309). Among those with and without cannabis predictors (any and frequent [≥3 times a week] non-medical use, DSM-IV cannabis use disorders [CUD], cannabis dependence [CD]), standardized prevalence of past-year self-reported psychotic disorders were estimated. Association was indicated by within-survey differences in psychotic disorders by cannabis-related predictor status. Whether associations changed over time was indicated by difference-in-difference tests (contrasts between the surveys).
Results In both surveys, self-reported psychotic disorders were significantly more prevalent in those with than those without any non-medical cannabis use (2001-2002: 1.65% vs 0.27%; 2012-2013: 1.89% vs. 0.68%), with similar associations in both periods. Self-reported psychotic disorders were unrelated to frequent non-medical use in 2001-2002 but were significantly more prevalent in those with than without frequent non-medical use in 2012-2013 (2.68% vs. 0.71%), with no significant difference over time. In both surveys, self-reported psychotic disorders were significantly more prevalent in those with than without CUD (2001-2002: 2.43% vs. 0.30%; 2012-2013: 3.26% vs. 0.72%), with no significant differences in the associations over time. Self-reported psychotic disorders were unrelated to CD in 2001-2002 but were significantly more prevalent in those with than without CD in 2012-2013 (8.54% vs. 0.73%), showing a significantly stronger relationship in 2012-2013; similarly, among past-year non-medical cannabis users, the association was significantly stronger in 2012-2013.
Conclusions Cannabis-related variables, especially cannabis dependence, remain related to self-reported psychotic disorders. Therefore, clinicians should closely monitor cannabis-dependent users and assess the need for preventive and therapeutic interventions for these individuals.
Competing Interest Statement
Dr. Hasin reports funding from Campbell Alliance for unrelated projects on the validation and use of a measure of opioid addiction among patients with chronic pain. All other authors report no financial relationships with commercial interests.
Funding Statement
Funding is acknowledged from the National Institute on Drug Abuse (R01DA034244, Hasin) and the New York State Psychiatric Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB committee not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures Dr. Hasin reports funding from Campbell Alliance for unrelated projects on the validation and use of a measure of opioid addiction among patients with chronic pain. All other authors report no financial relationships with commercial interests.
Data Availability
NESARC-III Datasets are available for investigators to request access through the National Institute of Alcohol Abuse and Alcoholism.
